260 related articles for article (PubMed ID: 18052607)
1. Antibody-based HIV-1 vaccines: recent developments and future directions.
Montefiori D; Sattentau Q; Flores J; Esparza J; Mascola J;
PLoS Med; 2007 Dec; 4(12):e348. PubMed ID: 18052607
[TBL] [Abstract][Full Text] [Related]
2. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
3. HIV/AIDS: allied responses.
Mascola JR
Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
[No Abstract] [Full Text] [Related]
4. Tailored immunogens for rationally designed antibody-based HIV-1 vaccines.
Mouquet H
Trends Immunol; 2015 Aug; 36(8):437-9. PubMed ID: 26169255
[TBL] [Abstract][Full Text] [Related]
5. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.
Montefiori DC
Springer Semin Immunopathol; 1997; 18(3):371-90. PubMed ID: 9089955
[No Abstract] [Full Text] [Related]
6. Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1-infected individuals.
Inami S; Taniguchi N; Ishibashi K; Nagao T; Aoki I; Ishii N; Okuda K
AIDS; 1991 Sep; 5(9):1140-1. PubMed ID: 1930779
[No Abstract] [Full Text] [Related]
7. Serological responses to candidate AIDS vaccines.
Graham BS
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S145-8. PubMed ID: 7865290
[No Abstract] [Full Text] [Related]
8. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
9. [Development of a vaccine against HIV: is this aim accomplishable?].
Wagner R; Asbach B
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
[No Abstract] [Full Text] [Related]
10. New insights into protective humoral responses and HIV vaccines.
Stamatatos L; Davis D
AIDS; 2001; 15 Suppl 5():S105-15. PubMed ID: 11816158
[No Abstract] [Full Text] [Related]
11. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
[TBL] [Abstract][Full Text] [Related]
12. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
Mascola JR; D'Souza P; Gilbert P; Hahn BH; Haigwood NL; Morris L; Petropoulos CJ; Polonis VR; Sarzotti M; Montefiori DC
J Virol; 2005 Aug; 79(16):10103-7. PubMed ID: 16051803
[No Abstract] [Full Text] [Related]
14. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.
Doria-Rose NA; Altae-Tran HR; Roark RS; Schmidt SD; Sutton MS; Louder MK; Chuang GY; Bailer RT; Cortez V; Kong R; McKee K; O'Dell S; Wang F; Abdool Karim SS; Binley JM; Connors M; Haynes BF; Martin MA; Montefiori DC; Morris L; Overbaugh J; Kwong PD; Mascola JR; Georgiev IS
PLoS Pathog; 2017 Jan; 13(1):e1006148. PubMed ID: 28052137
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
16. Immunology. Immune activation with HIV vaccines.
Fauci AS; Marovich MA; Dieffenbach CW; Hunter E; Buchbinder SP
Science; 2014 Apr; 344(6179):49-51. PubMed ID: 24700849
[No Abstract] [Full Text] [Related]
17. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.
Haubrich RH; Takeda A; Koff W; Smith G; Ennis FA
J Infect Dis; 1992 Mar; 165(3):545-8. PubMed ID: 1538159
[TBL] [Abstract][Full Text] [Related]
18. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
19. Vaccines for control of HIV infections.
Sharma KB
J Indian Med Assoc; 1994 Jan; 92(1):27-8. PubMed ID: 8207277
[No Abstract] [Full Text] [Related]
20. Identification and specificity of broadly neutralizing antibodies against HIV.
McCoy LE; Burton DR
Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
